Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 13
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Emergent BioSolutions Inc
EBS
NYSE
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$7.00
-0.065
-0.92%
Dern. MÀJ: Oct 12, 7:49 PM
$6.90
-0.16
-2.27%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Emergent BioSolutions Financials
Emergent BioSolutions (EBS) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Emergent BioSolutions Sees Q3 Sales $110.000M-$130.000M vs $209.000M Est
Emergent BioSolutions (NYSE:EBS) sees Q3 sales of $110.000 million-$130.000 million vs $209.000 million analyst estimate.
Benzinga Newsdesk
PRO
Emergent BioSolutions Lowers FY2026 Sales Guidance from $720.000M-$760.000M to $645.000M-$675.000M vs $733.050M Est
Emergent BioSolutions (NYSE:EBS) lowers FY2026 sales outlook from $720.000 million-$760.000 million to $645.000 million-$675.000 million vs $733.050 million estimate.
Benzinga Newsdesk
PRO
Emergent BioSolutions Q2 Adj. EPS $0.60 Beats $0.11 Estimate, Sales $234.300M Beat $177.500M Estimate
Benzinga Newsdesk
PRO
Emergent BioSolutions Sees Q2 Sales $170.000M-$185.000M vs $186.000M Est
Emergent BioSolutions (NYSE:EBS) sees Q2 sales of $170.000 million-$185.000 million vs $186.000 million analyst estimate.
Benzinga Newsdesk
PRO
Emergent BioSolutions Affirms FY2026 Sales Guidance of $720.000M-$760.000M vs $735.000M Est
Emergent BioSolutions (NYSE:EBS) affirms FY2026 sales outlook from $720.000 million-$760.000 million to $720.000 million-$760.000 million vs $735.000 million estimate.
Benzinga Newsdesk
PRO
Emergent BioSolutions Q1 Adj. EPS $0.21 Beats $(0.25) Estimate, Sales $156.100M Beat $145.000M Estimate
Emergent BioSolutions (NYSE:EBS) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $(0.25) by 184 percent. This is a 71.62 percent decrease over earnings of $0.74 per share from
Benzinga Newsdesk
